MDMA is increasingly used in clinical research, but no cGMP process has yet been reported. We describe here the first fully validated cGMP synthesis of up to 5 kg (≈30 000 patient doses) of MDMA in a four-step process beginning with a noncontrolled starting material. The overall yield was acceptable (41-53%, over four steps), and the chemical purity of the final product was excellent, exceeding 99.9% of the peak area by HPLC in each of the four validation trials. The availability of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use, if encouraging results lead to FDA approval.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756783 | PMC |
| http://dx.doi.org/10.1021/acsomega.1c05520 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug Development.
Alzheimers Dement
December 2024
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Clinical outcome assessments (COAs) are an integral part of clinical trials. A fit-for-purpose COA with well-selected endpoints can help determine the efficacy of a therapeutic intervention in the condition studied. The selection of the appropriate outcome measures depends not only on the condition but also on the disease stage and type of intervention studied.
View Article and Find Full Text PDFDementia Care Practice.
Alzheimers Dement
December 2024
Sounds Good Choir, NFP, Downers Grove, IL, USA.
Background: Singing improves mood, social, and physical well-being (Pentikainen et al., 2021). Choral singing has therefore gained recognition as a highly recommended activity for older adults and persons with dementia to fight isolation (Petrovsky et al.
View Article and Find Full Text PDFIdentification and Validation of Potential Biomarkers and Therapeutic Targets of COVID-19-related Depression.
Comb Chem High Throughput Screen
January 2025
Department of Emergency, First Medical Center of Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China.
Background: The prevalence of depression in COVID-19 patients is notably high, disrupting daily life routines and compounding the burden of other chronic health conditions. In addition, to elucidate the connection between COVID-19 and depression, we conducted an analysis of commonly differentially expressed genes [co-DEGs], uncovering potential biomarkers and therapeutic avenues specific to COVID-19-related depression.
Methods: We obtained gene expression profiles from the Gene Expression Omnibus [GEO] database with strategic keyword searches ["COVID-19", "depression," and "SARS"].
Technology and Dementia Preconference.
Alzheimers Dement
December 2024
University of Oxford, Oxford, UK.
Background: Plasma biomarkers have emerged as a promising tool to detect the presence of Alzheimer's disease (AD) when cognitive symptoms have not yet emerged. However, there is also a pressing need to detect and track subtle cognitive change at the preclinical stage of AD for population screening purposes and to monitor disease progression at scale. A potential solution is remote cognitive assessment, yet it is still not extensively employed.
View Article and Find Full Text PDFDevelopment and validation of a prognostic nomogram for predicting outcomes in brainstem hemorrhage patients.
Sci Rep
January 2025
Department of Neurosurgery, Ji'an Central People's Hospital, Ji'an, Jiangxi, China.
Brainstem hemorrhage is a severe neurological condition with high mortality and poor prognosis. This study aims to develop and validate a prognostic model for brainstem hemorrhage to facilitate early prediction of patient outcomes, thereby supporting clinical decision-making. Clinical data from 140 patients with brainstem hemorrhage were collected.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!